NT5C3A and familial pancreatic carcinoma: To validate the in vitro therapeutic efficacy of this novel c-MYC-mRNA drug (3′UTRMYC1-18), the metastatic drug-resistant pancreatic cancer cell lines MIA-PaCa-2, PSN1, and PANC1 were used.